Wednesday, July 8, 2026

Drug profile · INN

desonide

desonide (DESOWEN) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 5
Pipeline programs 33
News articles 0
Drug details — desonide
US status
approved
Class
Route
TOPICAL
Patents
5
Programs
33
Data quality
0.84

Quick answer

desonide (DESOWEN) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN desonide
Brand DESOWEN
Mechanism Glucocorticoid receptor agonist
Target Glucocorticoid receptor
Route TOPICAL
Formulation AEROSOL, FOAM

Mechanism of action

Glucocorticoid receptor agonist

Primary target: Glucocorticoid receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Budesonide Phase 3 · Bausch + Lomb · Colitis, Ulcerative
  2. Budesonide Phase 3 · AstraZeneca · Asthma
  3. Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX Phase 3 · Teva Pharma · Asthma
  4. Budesonide oral suspension Phase 3 · Takeda · Eosinophilic Esophagitis (EoE)
  5. Budesonide/Formoterol SPIROMAX® Phase 3 · Teva Pharma · Asthma
  6. Budesonide/Formoterol fumarate dihydrate Phase 3 · Teva Pharma · Asthma
  7. Budesonide/formoterol Turbuhaler Phase 3 · AstraZeneca · Asthma
  8. C0251010 Phase 3 · First Biotech (Australia) · Idiopathic Inflammatory Myopathy (including dermatomyositis

Related & competitor drugs

  1. beclomethasone dipropionate Glucocorticoid receptor agonist
  2. betamethasone acetate Glucocorticoid receptor agonist
  3. betamethasone dipropionate Glucocorticoid receptor agonist
  4. betamethasone valerate Glucocorticoid receptor agonist
  5. budesonide Alimentary tract and metabolism (A07)
  6. clobetasol propionate Glucocorticoid receptor agonist

Related patents

  1. US 11413296

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 9119863

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 8975243

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 8497258

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 8324192

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is desonide?

desonide (DESOWEN) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for desonide?

DESOWEN is a marketed brand name for desonide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of desonide?

desonide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.